UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers

Pharmacogenetics and Genomics

Volumn 17, Issue 8, 2007, Pages 619-627

  Yoder Graber, Andrea L ^a   Ramírez, Jacqueline ^a   Innocenti, Federico ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Glucuronidation; Pharmacogenetics; Thyroxine; UGT1A1

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; LIVER ENZYME; RECOMBINANT ENZYME; THYROXINE; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; COMPLEMENTARY DNA; DRUG DERIVATIVE; FLAVONOID; FLAVOPIRIDOL; GLUCURONIC ACID; GLUCURONIDE; PIPERIDINE DERIVATIVE; SN38 GLU; SN38-GLU; THYROXINE GLUCURONIDE; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ARTICLE; CORRELATION ANALYSIS; ENZYME SUBSTRATE; FIRST PASS EFFECT; GASTROINTESTINAL TRACT; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE ACTION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; NONHUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROXINE METABOLISM; CHEMISTRY; ENZYMOLOGY; GENETICS; KINETICS; LIVER; METABOLISM; PHENOTYPE;

CAMPTOTHECIN; DNA, COMPLEMENTARY; FLAVONOIDS; GENOTYPE; GLUCURONATES; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; LIVER; MICROSOMES, LIVER; PHENOTYPE; PIPERIDINES; POLYMORPHISM, GENETIC; THYROXINE;

EID: 34447305506     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3280121fe9     Document Type: Article

References (38)

1. 14 in vivo. J Clin Invest 1963; 42:1134-1141.
2. Wu SY, Green WL, Huang WS, Hays MT, Chopra IJ. Alternate pathways of thryroid hormone metabolism. Thyroid 2005; 15:943-958.
3. Kato Y, Suzuki H, Ikushiro S, Yamada S, Degawa M. Decrease in serum thyroxine level by phenobarbital in rats is not necessarily dependent on increase in hepatic UDP-glucuronosyltransferase. Drug Metab Dispos 2005; 33:1608-1612.
4. McClain RM, Levin AA, Posch R, Downing JC. The effect of phenobarbital on the metabolism and excretion of thyroxine in rats. Toxicol Appl Pharmacol 1989; 99:216-228.
5. Beetstra JB, van Engelen JG, Karels P, van der Hoek HJ, de Jong M, Docter R, et al. Thyroxine and 3,3′,5-triiodothyronine are glucuronidated in rat liver by different uridine diphosphate-glucuronyltransferases. Endocrinology 1991; 128:741-746.
6. Liu J, Liu Y, Barter RA, Klaassen CD. Alteration of thyroid homeostasis by UDP-glucuronosyltransferase inducers in rats: a dose-response study. J Pharmacol Exp Ther 1995; 273:977-985.
7. Hood A, Hashmi R, Klaassen CD. Effects of microsomal enzyme inducers on thyroid-follicular cell proliferation, hyperplasia, and hypertrophy. Toxicol Appl Pharmacol 1999; 160:163-170.
8. Hood A, Klaassen CD. Differential effects of microsomal enzyme inducers on in vitro thyroxine (T(4)) and triiodothyronine (T(3)) glucuronidation. Toxicol Sci 2000; 55:78-84.
9. Hood A, Allen ML, Liu Y, Liu J, Klaassen CD. Induction of T(4) UDP-GT activity, serum thyroid stimulating hormone, and thyroid follicular cell proliferation in mice treated with microsomal enzyme inducers. Toxicol Appl Pharmacol 2003; 188:6-13.
10. Benedetti MS, Whomsley R, Baltes E, Tonner F. Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction. Eur J Clin Pharmacol 2005; 61:863-872.
11. Ohnhaus EE, Burgi H, Burger A, Studer H. The effect of antipyrine, phenobarbitol and rifampicin on thyroid hormone metabolism in man. Eur J Clin Invest 1981; 11:381-387.
12. Haidukewych D, Rodin EA. Chronic antiepileptic drug therapy: classification by medication regimen and incidence of decreases in serum thyroxine and free thyroxine index. Ther Drug Monit 1987; 9:392-398.
13. Chakova L, Karakhanian E, Dimitrov H, Lutakova E. Effect of antiepileptic drugs on the thyroid gland in children with epilepsy (preliminary report). Folia Med (Plovdiv) 1998; 40:80-83.
14. Eiris-Punal J, Del Rio-Garma M, Del Rio-Garma MC, Lojo-Rocamonde S, Novo-Rodriguez I, Castro-Gago M. Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism. Epilepsia 1999; 40:1761-1766.
15. Green WL. New questions regarding bioequivalence of levothyroxine preparations: a clinician's response. AAPS J 2005; 7:E54-E58.
16. Visser TJ, Kaptein E, van Toor H, van Raaij JA, van den Berg KJ, Joe CT, et al. Glucuronidation of thyroid hormone in rat liver: effects of in vivo treatment with microsomal enzyme inducers and in vitro assay conditions. Endocrinology 1993; 133:2177-2186.
17. Findlay KA, Kaptein E, Visser TJ, Burchell B. Characterization of the uridine diphosphate-glucuronosyltransferase-catalyzing thyroid hormone glucuronidation in man. J Clin Endocrinol Metab 2000; 85:2879-2883.
18. Visser TJ, Kaptein E, Gijzel AL, de Herder WW, Ebner T, Burchell B. Glucuronidation of thyroid hormone by human bilirubin and phenol UDP-glucuronyltransferase isoenzymes. FEBS Lett 1993; 324:358-360.
19. Fisher MB, Campanale K, Ackermann BL, VandenBranden M,Wrighton SA. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 2000; 28:560-566.
20. Jemnitz K, Vereczkey L. Ion-pair high-performance liquid chromatographic separation of two thyroxine glucuronides formed by rat liver microsomes. J Chromatogr B Biomed Appl 1996; 681:385-389.
21. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65:576-582.
22. Ramirez J, Iyer L, Journault K, Belanger P, Innocenti F, Ratain MJ, et al. In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res 2002; 19:588-594.
23. Innocenti F, Liu W, Chen P, Desai AA, Das S, Ratain MJ. Haplotypes of variants in the UDP-glucuronosyltransferase 1A9 and 1A1 genes. Pharmacogenet Genomics 2005; 15:295-301.
24. Innocenti F, Grimsley C, Das S, Ramirez J, Cheng C, Kuttab-Boulos H, et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002; 12:725-733.
25. Iyer L, King CD,Whitington PF, Green MD, Roy SK, Tephly TR, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101:847-854.
26. Hanioka N, Ozawa S, Jinno H, Ando M, Saito Y, Sawada J. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 2001; 31:687-699.
27. Kasai N, Sakaki T, Shinkyo R, Ikushiro S, Iyanagi T, Ohta M, et al. Metabolism of 26,26,26,27,27,27-F6-1 alpha,23S,25-trihydroxyvitamin D3 by human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 2005; 33:102-107.
28. Sakaguchi K, Green M, Stock N, Reger TS, Zunic J, King C. Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms. Arch Biochem Biophys 2004; 424:219-225.
29. Di Marco A, D'Antoni M, Attaccalite S, Carotenuto P, Laufer R. Determination of drug glucuronidation and UDP-glucuronosyltransferase selectivity using a 96-well radiometric assay. Drug Metab Dispos 2005; 33:812-819.
30. Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 2003; 31:1086-1089.
31. Watanabe Y, Nakajima M, Yokoi T. Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos 2002; 30:1462-1469.
32. Uchaipichat V, Mackenzie PI, Gio XH, Gardner-Stephen D, Galetin A, Houston JB, Miners JO. Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probecenid. Drug Metab Dispos 2004; 32:413-423.
33. Chouinard S, Tessier M, Vernouillet G, Gauthier S, Labrie F, Barbier O, et al. Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue. Mol Pharmacol 2006; 69:908-920.
34. Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J, et al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 2004; 14:329-332.
35. Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004; 14:501-515.
36. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?. Proc Natl Acad Sci U S A 1998; 95:8170-8174.
37. Lampe JW, Bigler J, Horner NK, Potter JD. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999; 9:341-349.
38. Ando Y, Hasegawa Y. Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metab Rev 2005; 37:565-574.